MCID: RHB021
MIFTS: 24

Rhabdomyosarcoma, Embryonal, 2

Categories: Genetic diseases, Fetal diseases, Rare diseases, Cancer diseases

Aliases & Classifications for Rhabdomyosarcoma, Embryonal, 2

MalaCards integrated aliases for Rhabdomyosarcoma, Embryonal, 2:

Name: Rhabdomyosarcoma, Embryonal, 2 54 71 29 69
Rmse2 71

Classifications:



External Ids:

OMIM 54 180295
MedGen 40 C1867234
MeSH 42 D018233

Summaries for Rhabdomyosarcoma, Embryonal, 2

UniProtKB/Swiss-Prot : 71 Rhabdomyosarcoma, embryonal, 2: A form of rhabdomyosarcoma, a highly malignant tumor of striated muscle derived from primitive mesenchymal cells and exhibiting differentiation along rhabdomyoblastic lines. Rhabdomyosarcoma is one of the most frequently occurring soft tissue sarcomas and the most common in children. It occurs in four forms: alveolar, pleomorphic, embryonal and botryoidal rhabdomyosarcomas.

MalaCards based summary : Rhabdomyosarcoma, Embryonal, 2, is also known as rmse2, and has symptoms including multinodular goiter and embryonal rhabdomyosarcoma. An important gene associated with Rhabdomyosarcoma, Embryonal, 2 is DICER1 (Dicer 1, Ribonuclease III). The drugs Cyclophosphamide and Dactinomycin have been mentioned in the context of this disorder. Affiliated tissues include liver, bone and bone marrow.

Description from OMIM: 180295

Related Diseases for Rhabdomyosarcoma, Embryonal, 2

Diseases in the Embryonal Rhabdomyosarcoma family:

Rhabdomyosarcoma, Embryonal, 2

Symptoms & Phenotypes for Rhabdomyosarcoma, Embryonal, 2

Clinical features from OMIM:

180295

Human phenotypes related to Rhabdomyosarcoma, Embryonal, 2:

32
id Description HPO Frequency HPO Source Accession
1 multinodular goiter 32 HP:0005987
2 embryonal rhabdomyosarcoma 32 HP:0006743

Drugs & Therapeutics for Rhabdomyosarcoma, Embryonal, 2

Drugs for Rhabdomyosarcoma, Embryonal, 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 145)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
2
Dactinomycin Approved Phase 3,Phase 2 50-76-0 2019 457193
3
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978
4
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
5
Morphine Approved, Investigational Phase 3,Phase 1,Phase 2 57-27-2 5288826
6
Everolimus Approved Phase 3,Phase 2 159351-69-6 6442177
7
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2 22916-47-8 4189
8
Sirolimus Approved, Investigational Phase 3,Phase 2 53123-88-9 5284616 6436030 46835353
9
Camptothecin Experimental Phase 3,Phase 2,Phase 1 7689-03-4
10 Alkylating Agents Phase 3,Phase 2,Phase 1
11 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
12 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
13 Anti-Infective Agents Phase 3,Phase 2,Phase 1
14 Antimitotic Agents Phase 3,Phase 2,Phase 1
15 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
16 Antirheumatic Agents Phase 3,Phase 2
17 Immunosuppressive Agents Phase 3,Phase 2
18 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
19 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
20 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
21 Antifungal Agents Phase 3,Phase 2
22
Doxorubicin Approved, Investigational Phase 2,Phase 1 23214-92-8 31703
23
Etoposide Approved Phase 2 33419-42-0 36462
24
Ifosfamide Approved Phase 2 3778-73-2 3690
25
Lenograstim Approved Phase 2 135968-09-1
26
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
27
Mechlorethamine Approved Phase 2 51-75-2 4033
28
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
29
Bevacizumab Approved, Investigational Phase 2 216974-75-3
30
Vinblastine Approved Phase 2 865-21-4 13342 241903
31
Vinorelbine Approved, Investigational Phase 2 71486-22-1 60780 44424639
32
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
33
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
34
Oxaliplatin Approved, Investigational Phase 2,Phase 1 61825-94-3 5310940 9887054 43805 6857599
35
Etanercept Approved, Investigational Phase 2 185243-69-0
36
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
37
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
38
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
39
Epirubicin Approved Phase 2 56420-45-2 41867
40
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
41
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
42
Oprelvekin Approved, Investigational Phase 2 145941-26-0
43
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 446556 60843
44
Dasatinib Approved, Investigational Phase 1, Phase 2 302962-49-8 3062316
45
Olaparib Approved Phase 2 763113-22-0 23725625
46
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314
47
Edetic Acid Approved, Vet_approved Phase 2 60-00-4, 62-33-9 6049
48
Fludarabine Approved Phase 1, Phase 2 21679-14-1, 75607-67-9 30751
49
Adenosine Approved, Investigational Phase 2 58-61-7 60961
50
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903

Interventional clinical trials:

(show top 50) (show all 54)

id Name Status NCT ID Phase Drugs
1 Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma Completed NCT00354835 Phase 3 Irinotecan Hydrochloride;Cyclophosphamide;Vincristine Sulfate
2 Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma Active, not recruiting NCT00075582 Phase 3 dactinomycin;cyclophosphamide;vincristine sulfate
3 Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma Suspended NCT02567435 Phase 3 Cyclophosphamide;Irinotecan Hydrochloride;Temsirolimus;Vincristine Sulfate
4 Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Embryonal Rhabdomyosarcoma Unknown status NCT00245141 Phase 2 cyclophosphamide;vincristine sulfate
5 Vincristine, Dactinomycin, and Cyclophosphamide in Treating Patients With Embryonal Rhabdomyosarcoma Unknown status NCT00245089 Phase 2 cyclophosphamide;vincristine sulfate
6 Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma Completed NCT00025363 Phase 2 vincristine sulfate;irinotecan hydrochloride;cyclophosphamide;doxorubicin hydrochloride;ifosfamide;etoposide;tirapazamine
7 Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma Completed NCT01055314 Phase 2 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Irinotecan Hydrochloride;Temozolomide;Vincristine Sulfate Liposome
8 Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma Completed NCT01222715 Phase 2 Cyclophosphamide;Temsirolimus;Vinorelbine Tartrate
9 Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer Completed NCT01502410 Phase 2 sorafenib tosylate
10 Irinotecan in Treating Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
11 Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors Completed NCT00070109 Phase 2 trabectedin
12 Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Completed NCT00831844 Phase 2
13 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2 oxaliplatin
14 Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant Completed NCT00309907 Phase 2 methylprednisolone
15 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
16 Ixabepilone in Treating Young Patients With Refractory Solid Tumors Completed NCT00331643 Phase 2 ixabepilone
17 Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors Completed NCT00025441 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
18 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or Sarcoma Completed NCT00003955 Phase 2 cyclophosphamide;irinotecan hydrochloride;vincristine sulfate
19 A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma Completed NCT00668148 Phase 2
20 Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer Completed NCT00003408 Phase 2
21 New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma Completed NCT00001335 Phase 2 ADR-529;Topotecan;G-CSF
22 Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors Completed NCT00004157 Phase 2
23 Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation Completed NCT00003887 Phase 2
24 A Study of Pemetrexed in Children With Recurrent Cancer Completed NCT00520936 Phase 2 pemetrexed
25 Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation Completed NCT00002673 Phase 2
26 Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma Recruiting NCT03041701 Phase 1, Phase 2 Dasatinib;Ganitumab
27 Proton RT for the Treatment of Pediatric Rhabdomyosarcoma Recruiting NCT00592592 Phase 2
28 Pediatric MATCH: PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations Recruiting NCT03213678 Phase 2 PI3K/mTOR Inhibitor LY3023414
29 Pediatric MATCH: Trk Inhibitor LOXO-101 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions Recruiting NCT03213704 Phase 2 Larotrectinib
30 Pediatric MATCH: Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes Recruiting NCT03233204 Phase 2 Olaparib
31 Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Recruiting NCT02867592 Phase 2 Cabozantinib S-malate
32 Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders Recruiting NCT03155620 Phase 2 Ensartinib;Erdafitinib;Larotrectinib;Olaparib;PI3K/mTOR Inhibitor LY3023414;Selumetinib Sulfate;Tazemetostat;Vemurafenib
33 Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors Recruiting NCT02100891 Phase 2 Donor NK Cell Infusion
34 To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors Recruiting NCT01962103 Phase 1, Phase 2 nab-paclitaxel
35 A Study Comparing Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping Recruiting NCT02509598 Phase 2 Tc99m tilmanocept;Vital Blue Dye
36 Trial of Afatinib in Pediatric Tumours Recruiting NCT02372006 Phase 1, Phase 2 afatinib
37 Pediatric MATCH: Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations Recruiting NCT03213665 Phase 2 Tazemetostat
38 Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Active, not recruiting NCT01614795 Phase 2 temsirolimus
39 Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma Active, not recruiting NCT00923351 Phase 1, Phase 2 Tumor Purged/CD25 Depleted Lymphocytes;rhIL-7
40 Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia Active, not recruiting NCT01154816 Phase 2 Alisertib
41 Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma Active, not recruiting NCT00077285 Phase 2 carboplatin;cyclophosphamide;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;ifosfamide;irinotecan hydrochloride;vincristine sulfate
42 Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma Active, not recruiting NCT02452554 Phase 2
43 Pediatric MATCH: Pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations Not yet recruiting NCT03210714 Phase 2 Erdafitinib
44 Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors Withdrawn NCT02011126 Phase 2 imetelstat sodium
45 Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas Completed NCT00012181 Phase 1 alvocidib
46 Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors Completed NCT00093821 Phase 1 tanespimycin
47 Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas Completed NCT00101270 Phase 1 irinotecan hydrochloride;oxaliplatin
48 Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors Completed NCT00077454 Phase 1 erlotinib hydrochloride;temozolomide
49 Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma Completed NCT00720174 Phase 1 Doxorubicin Hydrochloride
50 Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma Completed NCT01241162 Phase 1

Search NIH Clinical Center for Rhabdomyosarcoma, Embryonal, 2

Genetic Tests for Rhabdomyosarcoma, Embryonal, 2

Genetic tests related to Rhabdomyosarcoma, Embryonal, 2:

id Genetic test Affiliating Genes
1 Rhabdomyosarcoma, Embryonal, 2 29

Anatomical Context for Rhabdomyosarcoma, Embryonal, 2

MalaCards organs/tissues related to Rhabdomyosarcoma, Embryonal, 2:

39
Liver, Bone, Bone Marrow, Testes, Endothelial, Thyroid, Lymph Node

Publications for Rhabdomyosarcoma, Embryonal, 2

Variations for Rhabdomyosarcoma, Embryonal, 2

ClinVar genetic disease variations for Rhabdomyosarcoma, Embryonal, 2:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 DICER1 NM_177438.2(DICER1): c.3907_3908delCT (p.Leu1303Valfs) deletion Pathogenic rs886037650 GRCh38 Chromosome 14, 95103488: 95103489
2 DICER1 NM_177438.2(DICER1): c.3611_3616delACTACAinsT (p.Tyr1204Leufs) indel Pathogenic rs886037651 GRCh38 Chromosome 14, 95103780: 95103785

Cosmic variations for Rhabdomyosarcoma, Embryonal, 2:

9 (show top 50) (show all 64)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM45255 TP53 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.668C>G p.P223R 8
2 COSM45005 TP53 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.739A>G p.N247D 8
3 COSM11081 TP53 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.733G>T p.G245C 8
4 COSM14271 PTPN11 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.1508G>T p.G503V 8
5 COSM13014 PTPN11 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.214G>A p.A72T 8
6 COSM13013 PTPN11 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.205G>A p.E69K 8
7 COSM13016 PTPN11 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.226G>C p.E76Q 8
8 COSM763 PIK3CA soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.1633G>A p.E545K 8
9 COSM775 PIK3CA soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.3140A>G p.H1047R 8
10 COSM580 NRAS soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.181C>A p.Q61K 8
11 COSM563 NRAS soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.34G>A p.G12S 8
12 COSM585 NRAS soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.183A>T p.Q61H 8
13 COSM574 NRAS soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.38G>T p.G13V 8
14 COSM584 NRAS soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.182A>G p.Q61R 8
15 COSM562 NRAS soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.34G>T p.G12C 8
16 COSM564 NRAS soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.35G>A p.G12D 8
17 COSM569 NRAS soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.37G>C p.G13R 8
18 COSM1745010 MYOD1 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.365T>G p.L122R 8
19 COSM516 KRAS soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.34G>T p.G12C 8
20 COSM553 KRAS soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.182A>T p.Q61L 8
21 COSM522 KRAS soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.35G>C p.G12A 8
22 COSM486 HRAS soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.37G>C p.G13R 8
23 COSM496 HRAS soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.181C>A p.Q61K 8
24 COSM481 HRAS soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.34G>T p.G12C 8
25 COSM483 HRAS soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.35G>T p.G12V 8
26 COSM480 HRAS soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.34G>A p.G12S 8
27 COSM5702570 FGFR1 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.1611G>T p.M537I 8
28 COSM5702566 DICER1 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.2809C>T p.R937C 8
29 COSM3738459 DICER1 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.5437G>A p.E1813K 8
30 COSM959251 DICER1 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.5113G>A p.E1705K 8
31 COSM3744763 DICER1 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.5428G>T p.D1810Y 8
32 COSM3738451 DICER1 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.5439G>T p.E1813D 8
33 COSM3738549 DICER1 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.5365-1G>T p.? 8
34 COSM393242 DICER1 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.2062C>T p.R688* 8
35 COSM4169595 DICER1 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.5425G>A p.G1809R 8
36 COSM5692 CTNNB1 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.134C>A p.S45Y 8
37 COSM5664 CTNNB1 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.121A>G p.T41A 8
38 COSM143842 ALK soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.3673G>A p.D1225N 8
39 COSM1651691 ALK soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.3830T>C p.I1277T 8
40 COSM5702542 ABL2 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.1045G>T p.V349L 8
41 COSM5702540 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.1108G>T p.V370L 8
42 COSM5702568 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.1611G>T p.M537I 8
43 COSM5702571 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.1611G>T p.M537I 8
44 COSM5702541 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.1090G>T p.V364L 8
45 COSM5702572 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.1611G>T p.M537I 8
46 COSM5702539 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.1153G>T p.V385L 8
47 COSM99938 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.37G>C p.G13R 8
48 COSM5702569 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.1581G>T p.M527I 8
49 COSM45253 TP53 soft tissue,striated muscle,rhabdomyosarcoma,alveolar c.611A>G p.E204G 6
50 COSM45256 TP53 soft tissue,striated muscle,rhabdomyosarcoma,alveolar c.871A>C p.K291Q 6

Expression for Rhabdomyosarcoma, Embryonal, 2

Search GEO for disease gene expression data for Rhabdomyosarcoma, Embryonal, 2.

Pathways for Rhabdomyosarcoma, Embryonal, 2

GO Terms for Rhabdomyosarcoma, Embryonal, 2

Sources for Rhabdomyosarcoma, Embryonal, 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....